Kate Morgan

co-Chief Exec at Myeloma Patients Europe. Interest in health policy and medicines access plus the occasional tweet about Scotland and travel. Views mine.

[Myeloma Patients Europe @MyelomaEurope]

We asked patients, carers, clinicians, researchers and stakeholders about the biggest challenges in #myeloma and how MPE can make a difference. Their insights helped shape our new Strategic Goals 2025 – 2030. These will drive our work in the coming years.
https://t.co/Qemw87rqXI

[Charlotte Pawlyn @_DrCP]

We are looking for a new consultant colleague (10 PA, substantive NHS post). Great opportunity for anyone with an interest in myeloma who wants to join an academic centre. https://t.co/vvIAZhIkv6

[Myeloma Patients Europe @MyelomaEurope]

MPE Co-CEO, Katie Joyner, spoke at @EMN_EuMMnet's 5th annual meeting, highlighting the importance of empowering European patients to access clinical trial information.

¨Patients deserve accurate, comprehensive information for informed discussions with healthcare teams.¨

[Bruno Paiva @BrunoPaiva_UNAV]

ODAC unanimously votes in favor of using #MRD as an early endpoint for accelerated approval in #myeloma trials

This was a huge team effort for more than 8 years and with the generosity of unprecedented data sharing from many investigators around the world. Thank you all!
#mmsm

[Myeloma Patients Europe @MyelomaEurope]

@US_FDA's Oncologic Drugs Advisory Committee (ODAC) recognises Minimal Residual Disease (MRD) as an accepted endpoint for accelerated approval in myeloma.
Read more information here: https://t.co/7WQyLSDCLs
@OncLive
#myeloma #MRD

[OncLive.com @OncLive]

BREAKING: @US_FDA’s ODAC Recognizes MRD as an Accepted End Point for Accelerated Approval in Multiple Myeloma #mmsm #oncology https://t.co/ybz7hnswyV

[Multiple Myeloma RF @theMMRF]

Today, US FDA held an ODAC meeting to debate MRD as an endpoint to support accelerated approval in #myeloma clinical trials. Two groups (@SylvesterCancer and i2TEAMM) presented retrospective data from clinical trials that measured MRD. Final vote was 12-0 in favor.

[Myeloma Patients Europe @MyelomaEurope]

.@EMA_News CHMP gives positive recommendation on #CART-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory #myeloma

https://t.co/Rx9nBSSx9c

[Myeloma Patients Europe @MyelomaEurope]

Commissioner @SKyriakidesEU highlights #EUCancerPlan progress, including the first EU network linking National Comprehensive Cancer Centres in every MS, but discussions show more work remains to tackle inequalities, among other issues.
#WorldCancerDay

[Myeloma Patients Europe @MyelomaEurope]

EU funded project @ASCERTAIN_EU , of which MPE is a partner, is in its second year! The Consortium meeting ended yesterday with presentations on the project’s progress, followed by discussions and suggestions from partners and advisory board members
https://t.co/e0JRUdM0Qd

[Myeloma Patients Europe @MyelomaEurope]

Led by @EHA_hematology, with the involvement of MPE, the article "Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials" is now published! An important step in improving the collection of #PROs.
https://t.co/vGgoJ2NHq8

[Myeloma Patients Europe @MyelomaEurope]

@EMA_News CHMP confirms recommendation for non-renewal of Blenrep marketing authorisation.

Read more about it here: https://t.co/graz8KNBEO

[Myeloma Patients Europe @MyelomaEurope]

MPE is a partner in an exciting new @HorizonEU project called #CERTAINTY, which explores the role of virtual twins in CAR-T and personalised #myeloma care.

You can explore further information about the project here:

[Myeloma Patients Europe @MyelomaEurope]

Great to see so many patient advocates presenting relevant research at the #ASH23 poster sessions. Congratulations! 1/1
@MyelomaUK @AcuteLeuk

[Myeloma Patients Europe @MyelomaEurope]

The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory #myeloma
https://t.co/Qa9TWtqVVW

[Myeloma Patients Europe @MyelomaEurope]

#ASH23 has already started for the MPE team! Ready to learn about the more important updates on #myeloma and #ALamyloidosis and meet friends and colleagues

[Kate Morgan @KateEMor_]

The brilliant @SamanthaNier highlighting results of @AcuteLeuk #carer survey and the unmet needs for support. #ASH2023 @pfizer #advocacybreakfast

[Myeloma Patients Europe @MyelomaEurope]

Participate in our myeloma survey on shared decision-making! Share your experiences to improve communication between patients and healthcare professionals.
Available in English, Hebrew, Slovenian, German, Spanish, French, Dutch, and Swedish
https://t.co/tMvYWBkqKJ

[Myeloma Patients Europe @MyelomaEurope]

Congratulations to our colleagues at @KU_Leuven, who will present a poster today at @ISPORorg 2023 on the work MPE and our Israeli member AMEN have been supporting on shared decision making.
https://t.co/elWm9SsGHP

[European Patients' Forum @eupatientsforum]

📣Are you interested in leading an organisation with the mission of advocating for HIV patients? @EATGx is hiring a new Executive Director!

EATG represents a network of more than 150 members, from 45 countries in Europe.

Apply below!

👉https://t.co/LCGbLrlMJs